Skip to content

Author

Catherine Zhang

We have 3 of 6 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

Engineered stem cell-derived CD16-enhanced universal NKT cells improve monoclonal antibody-based cancer immunotherapy.

Monoclonal antibody (mAb)-based therapies have revolutionized cancer treatment; however, their clinical efficacy is often limited by insufficient antibody-dependent cellular cytotoxicity (ADCC), tumor antigen escape, and an immunosuppressive tumor microenvironment (TME). To overcome these limitations, we developed an a...

Yan-Ruide Li, Yi-Chen Zhu, Yan-Qi Yu et al. · 0 citations
Review Oct 2026

Decoding Innate T Cell Functionality in Tumor Immunity and Therapeutic Response

Innate T cells, including invariant natural killer T (iNKT) cells, mucosal-associated invariant T (MAIT) cells, and γδ T cells, bridge innate and adaptive immunity through rapid responses to nonpeptide antigens, metabolites, and stress-associated signals. In cancer, these populations can promote tumor surveillance thro...

Yu-Ning Chen, Annabel S. Zhao, Catherine Zhang et al. · 0 citations
Open access Aug 2026

Scalable generation of hematopoietic stem cell-engineered off-the-shelf mono-specific cytotoxic T cells targeting solid tumors

HSPC-derived AlloESO-T cells are established as an off-the-shelf, mono-specific cytotoxic T cell therapy with scalable manufacturing, enhanced efficacy, and improved safety, which support broad applicability of AlloESO-T cells across solid tumors.

Yi-Chen Zhu, Jia-Ji Yu, Y. J. Kim et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.